Kofi 2012-08-08 04:00:36
Androgens affect OCTN2 and carnitine uptake in the gut. This, in turn,
allows butyrate uptake which regulates epigenetics. Butyrate is a
I wouldn’t be surprised if androgen deprivation didn’t also turn up as
problematic for the heart for these same reasons.
Prostate Cancer Treatment Linked to Higher Rate of Colon Cancer, Study
ScienceDaily (Jan. 19, 2011) Men treated with hormone-based therapy
for prostate cancer faced a 30 percent to 40 percent higher risk of
colorectal cancer, compared to patients who did not receive this
treatment, according to a new study.
The study looked at use of androgen deprivation therapy, a common type
of treatment for prostate cancer that involves blocking the male hormone
testosterone through either surgical removal of the testicles or a
series of injections. It’s been shown to benefit men with advanced
cancers, but its benefit for less-advanced disease is unclear. Still,
more than half a million men in the United States currently receive this
Researchers looked at data from 107,859 men aged 67 and older with
prostate cancer, identified through the Surveillance, Epidemiology and
End Results and Medicare linked database, which provides information
about older adults with newly diagnosed cancer. Results of the study
were published online in the Journal of the National Cancer Institute.
The study is the first to link androgen deprivation therapy for prostate
cancer to an increased risk of colorectal cancer. The researchers found
that the risk increased the longer a man received androgen deprivation
therapy. Patients who had their testicles removed, a procedure called
orchiectomy, had the highest rates of colorectal cancer.
Overall, the risk of colorectal cancer was still low — less than 1
percent per year even among orchiectomy patients. But any increased risk
should be carefully considered when using androgen deprivation therapy
in cases when its benefit is not clear, the researchers say.
“Androgen deprivation therapy still continues to be used in situations
where there are not evidence-based studies showing its benefit. When
androgen deprivation therapy is clearly known to be beneficial, people
should not shy away from using it. But where there’s not solid evidence,
this is potentially another harm,” says lead study author Vahakn B.
Shahinian, M.D., M.S., assistant professor of internal medicine at the
University of Michigan Medical School and a member of the U-M
Comprehensive Cancer Center.
Shahinian stresses that androgen deprivation therapy can be lifesaving
for certain men with prostate cancer, and those patients should not
hesitate to use it. The study authors suggest that continued routine
preventive care, including colorectal cancer screening, is important
during prostate cancer treatment.
Funding was provided by the National Cancer Institute, Sassella Stiftung
Zurich, and Union Bank of Switzerland.
Prostate cancer statistics: 217,730 Americans will be diagnosed with
prostate cancer this year and 32,050 will die from the disease,
according to the American Cancer Society.
The above story is reprinted (with editorial adaptations by ScienceDaily
staff) from materials provided by University of Michigan Health System.
1. Silke Gillessen, Arnoud Templeton, Giancarlo Marra, Yong-Fang Kuo,
Emanuele Valtorta, and Vahakn B. Shahinian. Risk of colorectal cancer in
men on long-term androgen deprivation therapy for prostate cancer.
Journal of the National Cancer Institute, November 10, 2010 DOI: